Product Description
AZD1236 is a potent and reversible inhibitor of human MMP-9 and MMP-12 (IC50 = 4.5 and 6.1nM, respectively), with >10-fold selectivity to MMP-2 and MMP-13 and >350-fold selectivity to other members of the enzyme family. AZD1236 activity is approximately 20 to 50-fold lower at the rat, mouse, and guinea pig orthologues. In acute models of lung injury, AZD1236 inhibited the haemorrhage and inflammation induced by instillation of human MMP-12 into rat lungs by ~80% at 0.81mg/kg, and also abolished macrophage infiltration into BAL fluid induced by tobacco smoke inhalation in the mouse. (Sourced from: https://openinnovation.astrazeneca.com/clinical-research/clinical-molecules/azd1236.html)
Mechanisms of Action: MMP Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Chronic Obstructive Pulmonary Disease|Cystic Fibrosis
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CYBER | P2 |
Terminated |
Cystic Fibrosis |
2009-08-28 |
|
| BICO | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2009-08-20 |
|
| 2008-002230-30 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2009-07-21 |
|
| BICO | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2009-05-01 |